Why the study?
While renin-angiotensin system inhibitors are under scrutiny for cancer metastasis treatment, the administration of ACE inhibitors has been described to accompany carcinogenic effects.
Do angiotensin-converting enzyme inhibitors (ACEIs) increase the risk of lung cancer?
Do angiotensin-converting enzyme inhibitors (ACEIs) increase the risk of lung cancer?
This mini-review highlights recent evidence suggesting a potential association between ACE inhibitor use and increased lung cancer risk.
Scrutiny of RAS inhibitors in select conditions leaves open safety questions; does not alter current ACEI indications.
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.
No takes yet. Share an insight, caveat, or question.
Asgharpour et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: